Article ; Online: Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.
Journal of clinical hypertension (Greenwich, Conn.)
2020 Volume 22, Issue 8, Page(s) 1379–1388
Abstract: ... This study investigated possible relationships between anti-hypertensive medications use and COVID-19 ... associated with increased risk of COVID-19. Considering anti-hypertensive drugs, receiving diuretics (HR: 1 ... cohort study involving 34 936 hypertensive adults >50 years in Tarragona (Southern Catalonia, Spain) who were ...
| Abstract | The use of some anti-hypertensive drugs in the current COVID-19 pandemic has become controversial. This study investigated possible relationships between anti-hypertensive medications use and COVID-19 infection risk in the ambulatory hypertensive population. This is a population-based retrospective cohort study involving 34 936 hypertensive adults >50 years in Tarragona (Southern Catalonia, Spain) who were retrospectively followed through pandemic period (from 01/03/2020 to 30/04/2020). Two data sets including demographic/clinical characteristics (comorbidities and cardiovascular medications use) and laboratory PCR codes for COVID-19 were linked to construct an anonymized research database. Cox regression was used to calculate multivariable hazard ratios (HRs) and estimate the risk of suffering COVID-19 infection. Across study period, 205 PCR-confirmed COVID-19 cases were observed, which means an overall incidence of 586.8 cases per 100 000 persons-period. In multivariable analyses, only age (HR: 1.03; 95% CI: 1.02-1.05; P < .001) and nursing home residence (HR: 19.60; 95% CI: 13.80-27.84; P < .001) appeared significantly associated with increased risk of COVID-19. Considering anti-hypertensive drugs, receiving diuretics (HR: 1.22; 95% CI: 0.90-1.67; P = .205), calcium channel blockers (HR: 1.29; 95%CI: 0.91-1.82; P = .148), beta-blockers (HR: 0.97; 95% CI: 0.68-1.37; P = .844), and angiotensin-converting enzyme inhibitors (HR: 0.83; 95% CI: 0.61-1.13; P = .238) did not significantly alter the risk of PCR-confirmed COVID-19, whereas receiving angiotensin II receptor blockers was associated with an almost statistically significant reduction risk (HR: 0.67; 95% CI: 0.44-1.01; P = .054). In conclusion, our data support that receiving renin-angiotensin-aldosterone system inhibitors does not predispose for suffering COVID-19 infection in ambulatory hypertensive people. Conversely, receiving angiotensin II receptor blockers could be related with a reduced risk. |
|---|---|
| MeSH term(s) | Adrenergic beta-Antagonists/adverse effects ; Adrenergic beta-Antagonists/therapeutic use ; Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/adverse effects ; Antihypertensive Agents/therapeutic use ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19/virology ; Calcium Channel Blockers/adverse effects ; Calcium Channel Blockers/therapeutic use ; Case-Control Studies ; Comorbidity ; Diuretics/adverse effects ; Diuretics/therapeutic use ; Female ; Humans ; Hypertension/complications ; Hypertension/drug therapy ; Incidence ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Renin-Angiotensin System/drug effects ; Retrospective Studies ; Risk Factors ; SARS-CoV-2/drug effects ; SARS-CoV-2/genetics ; Spain/epidemiology |
| Chemical Substances | Adrenergic beta-Antagonists ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Calcium Channel Blockers ; Diuretics |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-07-25 |
| Publishing country | United States |
| Document type | Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2077222-1 |
| ISSN | 1751-7176 ; 1524-6175 |
| ISSN (online) | 1751-7176 |
| ISSN | 1524-6175 |
| DOI | 10.1111/jch.13948 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5723: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.